Nektar Therapeutics | NKTR - Selling And Administration Expenses


Nektar Therapeutics reported $11.87M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
ALKERMES USD 196.64M 67.96M Jun/2026
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Amgen USD 1.72B 134M Jun/2026
Baxter International USD 735M 7M Jun/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
Biogen USD 709.7M 155.4M Jun/2026
Bristol-Myers Squibb USD 1.83B 209M Jun/2026
Cara Therapeutics USD 2.09M 96K Mar/2026
Cipla INR 13.25B 101.8M Dec/2025
Dr.Reddys Laboratories INR 26.1B 11.63B Jun/2026
Eisai JPY 114.83B 4.71B Jun/2026
Eli Lilly USD 3.43B 496M Jun/2026
Exelixis USD 147.63M 8.03M Jun/2026
Gilead Sciences USD 1.52B 70M Jun/2026
GlaxoSmithKline GBP 2.19B 75M Jun/2026
Grifols EUR 320.45M 12.65M Dec/2025
Halozyme Therapeutics USD 57M 10.71M Jun/2026
Incyte USD 351.73M 23.64M Jun/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Ironwood Pharmaceuticals USD 33.33M 2.78M Dec/2024
Karyopharm Therapeutics USD 10.42M 861K Mar/2026
MacroGenics USD 9.71M 1.77M Mar/2026
Merck USD 2.89B 219M Jun/2026
Nektar Therapeutics USD 11.87M 1.7M Mar/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Novartis USD 3.24B 101M Jun/2026
Pfizer USD 3.41B 496M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
Takeda JPY 286.51B 5.48B Jun/2026
Teva Pharmaceutical Industries USD 1.03B 34M Jun/2026
Xencor USD 77.54M 4.59M Jun/2026